Richard Gaynor

Richard Gaynor

Company: Neon Therapeutics

Job title: President of R&D


Neoantigen Therapeutics Come of Age 5:25 pm

• Discuss experience utilizing a personal neoantigen vaccine in combination with a checkpoint inhibitor and, in certain cases, chemotherapy, to treat patients with high mutational burden tumors in the metastatic setting • Outline Neon’s personalized T cell approach, investigating ex vivo immunization of multiple T cell populations that are generated to target each individual patient’s…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.